Physician profile
Ranjit Cordeiro
NPI 1417950957
$1,070.13
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $40.57 · 2021: $212 · 2022: $301 · 2023: $147 · 2024: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $239.28 | 2019-2024 | Auryxia |
| Alexion Pharmaceuticals, INC. | $152.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $123.96 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $89.73 | 2019-2023 | Korsuva, Velphoro |
| Aurinia Pharma U.S., INC. | $77.74 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $66.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.44 | 2023-2024 | Jardiance |
| Amgen INC. | $56.58 | 2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $53.44 | 2021-2022 | |
| Novo Nordisk INC | $32.46 | 2024 | |
| Dexcom, INC. | $26.51 | 2021 | |
| Vifor Pharma, INC. | $24.06 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.07 | 2023 | |
| Glaxosmithkline, LLC. | $18.28 | 2021 | |
| Ardelyx, INC. | $16.74 | 2024 | Ibsrela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.65 | 2023 | Dalvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Cordeiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.